Form 8-K - Current report:
SEC Accession No. 0000950170-25-092964
Filing Date
2025-07-02
Accepted
2025-07-02 16:12:32
Documents
10
Period of Report
2025-06-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-20250627.htm   iXBRL 8-K 48494
  Complete submission text file 0000950170-25-092964.txt   160282

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20250627.xsd EX-101.SCH 26082
12 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20250627_htm.xml XML 4932
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 251101122
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)